Lanifibranor clinical trials
Also written IVA337.
How each study uses lanifibranor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Inventiva Pharma (5) · University of Florida (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Studies
Open first, then newest update. How each study uses lanifibranor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )Active, not recruitingPhase 3Inventiva PharmaNCT04849728Written as IVA337
- Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusCompletedPhase 2Inventiva PharmaNCT05232071Written as Lanifibranor
- Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver DiseaseCompletedPhase 2University of FloridaNCT03459079Written as Lanifibranor
- A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese SubjectsCompletedPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06126562Written as Lanifibranor
- Phase 2b Study in NASH to Assess IVA337CompletedPhase 2Inventiva PharmaNCT03008070Written as IVA337
- Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic DoseCompletedPhase 1Inventiva PharmaNCT03866369Written as Lanifibranor
- Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic SclerosisCompletedPhase 2Inventiva PharmaNCT02503644Written as IVA337
Codes
What other systems call lanifibranor · ClinicalTrials.gg INT000684
- MeSH (NLM) C000619516lanifibranorConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 28Q8AG0PYLLANIFIBRANORConfirmed FDA, NLM, Wikidata
- Wikidata Q27896056lanifibranorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C166556LanifibranorOne source FDA
- DrugBank DB14801One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619516 | lanifibranor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 28Q8AG0PYL | LANIFIBRANOR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27896056 | lanifibranor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C166556 | Lanifibranor | One source FDA |
| DrugBank | DB14801 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.